Valid for Submission
D89.41 is a billable diagnosis code used to specify a medical diagnosis of monoclonal mast cell activation syndrome. The code D89.41 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
Index to Diseases and Injuries
The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code D89.41 are found in the index:
Diagnostic Related Groups - MS-DRG Mapping
|MS-DRG||MS-DRG Title||MCD||Relative Weight|
|814||RETICULOENDOTHELIAL AND IMMUNITY DISORDERS WITH MCC||16||1.8907|
|815||RETICULOENDOTHELIAL AND IMMUNITY DISORDERS WITH CC||16||0.9925|
|816||RETICULOENDOTHELIAL AND IMMUNITY DISORDERS WITHOUT CC/MCC||16||0.6609|
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
D8941 replaces the following previously assigned ICD-10 code(s):
Convert D89.41 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code D89.41 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.